Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis.
作者信息
Bamias Giorgos, Rivera-Nieves Jesús, Mantzaris Gerassimos J
机构信息
GI-Unit, 3(rd) Academic Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Medicine, Division of Gastroenterology, San Diego, California.
出版信息
Gastroenterology. 2020 May;158(6):1836-1837. doi: 10.1053/j.gastro.2020.03.024. Epub 2020 Mar 19.
Abstract
摘要
相似文献
1
Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis.白细胞介素12/23阻断疗法的疗效拓宽了我们的治疗靶点，并对溃疡性结肠炎的旧有观念提出了挑战。
Gastroenterology. 2020 May;158(6):1836-1837. doi: 10.1053/j.gastro.2020.03.024. Epub 2020 Mar 19.
2
Ustekinumab for treating ulcerative colitis: an expert opinion.乌司奴单抗治疗溃疡性结肠炎：专家意见。
Expert Opin Biol Ther. 2020 Nov;20(11):1321-1329. doi: 10.1080/14712598.2020.1792882. Epub 2020 Jul 24.
3
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.在中重度溃疡性结肠炎中定位乌司奴单抗：新的竞争者。
Expert Opin Biol Ther. 2020 Apr;20(4):421-427. doi: 10.1080/14712598.2020.1727437. Epub 2020 Feb 13.
4
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.乌司奴单抗药代动力学和在溃疡性结肠炎 3 期随机试验中的暴露反应。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2244-2255.e9. doi: 10.1016/j.cgh.2019.11.059. Epub 2019 Dec 7.
5
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.英夫利昔单抗治疗难治性或不耐受性溃疡性结肠炎的临床疗效。
United European Gastroenterol J. 2020 Feb;8(1):91-98. doi: 10.1177/2050640619895361. Epub 2019 Dec 12.
6
Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.优特克单抗用于治疗与免疫检查点抑制剂相关的难治性结肠炎。
N Engl J Med. 2021 Feb 11;384(6):581-583. doi: 10.1056/NEJMc2031717.
7
Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab.乌司奴单抗快速诱导和维持难治性溃疡性结肠炎缓解
Diseases. 2019 Sep 28;7(4):55. doi: 10.3390/diseases7040055.
8
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.乌司奴单抗诱导和维持溃疡性结肠炎的治疗。
N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.
9
Anti-interleukin-23 agents for the treatment of ulcerative colitis.抗白细胞介素-23 制剂治疗溃疡性结肠炎。
Expert Opin Biol Ther. 2020 Apr;20(4):399-406. doi: 10.1080/14712598.2020.1697227. Epub 2019 Nov 27.
10
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.人群药代动力学和暴露-反应建模分析乌司奴单抗在中重度活动性溃疡性结肠炎成人患者中的应用。
J Clin Pharmacol. 2020 Jul;60(7):889-902. doi: 10.1002/jcph.1582. Epub 2020 Feb 5.
引用本文的文献
1
Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.乌司奴单抗治疗难治性 pouchitis 和慢性 pouch 炎的效果如何？一项系统评价。
Dig Dis Sci. 2022 Jun;67(6):1948-1955. doi: 10.1007/s10620-021-07002-5. Epub 2021 Jun 7.
2
Interleukin-12B gene rs6887695 and rs2288831 polymorphisms are associated with an increased risk of ulcerative colitis development in Chinese Han population: A case-control study.白细胞介素-12B 基因 rs6887695 和 rs2288831 多态性与中国汉族人群溃疡性结肠炎发病风险增加相关：一项病例对照研究。
J Clin Lab Anal. 2020 Nov;34(11):e23472. doi: 10.1002/jcla.23472. Epub 2020 Jul 14.
Zotero 插件